Abstract
Data on prevalence of SARS-CoV-2 antibody in healthcare workers (HCWs) is scare, especially in pediatric settings. The purpose of this study was to evaluate the SARS-CoV-2 IgG-positivity among HCWs of a tertiary pediatric hospital. In addition, follow-up of serological response in the subgroup of seropositive HCWs was performed, to get some insight on persistence of IgG antibodies to SARS-CoV-2. Free, voluntary SARS-CoV-2 IgG testing was made available to HCWs of the Children’s Memorial Health Institute in Warsaw (Poland). Plasma samples were collected between July 1 and August 9, 2020 and tested using the Abbott SARS-CoV-2 IgG assay. Of 2282 eligible participants, 1879 (82.3%) HCWs volunteered to undergo testing. Sixteen HCWs tested positive for SARS-CoV-2 IgG, corresponding to the seroprevalence of 0.85%. Among seropositive HCWs, three had confirmed COVID-19. Of note, 8 (50%) seropositive HCWs reported neither symptoms nor unprotected contact with confirmed SARS-CoV-2 cases in the previous months. A decline in the IgG index was observed at median time of 86.5 days (range:84-128 days) after symptom onset or RT-PCR testing. The nationwide public health response measures together with infection prevention and control practices implemented at the hospital level, at the beginning of the COVID-19 pandemic, might explain a low seroprevalence. Further studies are warranted to elucidate the duration of anti-SARS-CoV-2 antibodies, as well as the correlation between seropositivity and protective immunity against reinfection. Regardless of the persistence of antibodies and their protective properties, such low prevalence indicates that this population is vulnerable to a second wave of the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been reviewed and approved by the Institutional Review Board of the Children's Memorial Health Institute in Warsaw (Ref. no. 10/P-IN/20), and granted a waiver of consent since the data were analyzed anonymously.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data will be held in a public repository at https://data.mendeley.com
